Beijing: Amid coronavirus vaccine race, a Chinese pharmaceutical company on Thursday said the vaccine for highly contagious Coronavirus, it is developing should be ready by early 2021 for distribution worldwide, including the United States.
The CEO of SinoVac Yin Weidong swore to apply to the U.S. Food and Drug Administration for selling CoronaVac in US after passing its third and final round of testing in humans. Yin confirmed he personally has taken the experimental vaccine.
“At the very beginning, our strategy was designed for China and for Wuhan. Soon after that in June and July we adjusted our strategy, that is to face the world,” referring to the Wuhan, a Chinese city were the virus first emerged, Yin said.
“Our goal is to provide the vaccine to the world including the U.S., EU and others,” he added.
Stringent regulations in the U.S., European Union, Japan and Australia have blocked the sale of Chinese vaccines. Yin asserted that could change.
He further said that more than 24,000 people were participating in clinical trials of CoronaVac in Brazil, Turkey, and Indonesia, with more trials were scheduled for Bangladesh and perhaps in Chile.
According to Yin, SinoVac employees are qualified for emergency use of the vaccine because an outbreak inside the company would cripple its ability to develop a vaccine and about 90% of the company’s staff have received it.
“We are confident that our research of the COVI-19 vaccines can meet the standards of the U.S. and EU countries,” Yin asserted.
Yin Weidong, CEO of the Chinese pharmaceutical company SinoVac